| Cat. No. |
Product Name |
CAS No. |
Information |
| PC-72626 |
AT-527
|
2241337-84-6 |
AT-527 (AT527, Bemnifosbuvir hemisulfate, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM. |
| PC-63383 |
GSK-2878175
|
1423007-82-2 |
GSK-2878175 (GSK8175, GSK-175, GSK-175A) is a potent, pan-genotypic, second generation HCV NS5B palm polymerase inhibitor with EC50 of 0.4-9.7 nM. |
| PC-61440 |
Voxilaprevir
|
1535212-07-7 |
Voxilaprevir (GS-9857) is a potent HCV NS3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir for treatment of HCV infection.. |
| PC-60952 |
Deleobuvir
|
863884-77-9 |
Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity. |
| PC-60428 |
GSK-2485852
|
1331942-30-3 |
GSK-2485852 (GSK2485852, GSK5852) is a highly potent, selective HCV NS5B polymerase inhibitor with IC50 of 3.0 and 1.6 nM for HCV genotypes 1a and 1b in replicon assay, respectively. |
| PC-42412 |
PSI-6130
|
817204-33-4 |
PSI-6130 (R-1656) is a potent, specific inhibitor of HCV RNA synthesis by inhibiting the NS5B RNA polymerase (EC90=4.6 uM in replicon assay). |
| PC-73081 |
Amphihevir
|
1890171-61-5 |
Amphihevir is a potent, selective HCV NS4B inhibitor with EC50 of 0.34 and 1.97 nM against the GT1a (H77) and GT1b replicon in luciferase assays. |
